药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02268 药明合联

已收盘 07-29 16:08:21

53.000

-0.900

-1.67%

最高55.600	最低52.300	成交量588.25万
今开54.000	昨收53.900	日振幅6.12%
总市值670.98亿	流通市值670.98亿	总股本12.66亿
成交额3.15亿	换手率0.46%	流通股本12.66亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02268","market":"HK","secType":"STK","nameCN":"药明合联","latestPrice":53,"timestamp":1785312501000,"preClose":53.9,"halted":0,"volume":5882544,"delay":0,"changeRate":-0.01669758812615953,"floatShares":1266000000,"shares":1266000000,"eps":1.298276487882353,"marketStatus":"已收盘","change":-0.9,"latestTime":"07-29 16:08:21","open":54,"high":55.6,"low":52.3,"amount":315113225,"amplitude":0.061224,"askPrice":53.05,"askSize":4500,"bidPrice":53,"bidSize":7500,"shortable":3,"etf":0,"ttmEps":1.298276487882353,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785375000000},"marketStatusCode":5,"adr":0,"listingDate":1700150400000,"exchange":"SEHK","adjPreClose":53.9,"openAndCloseTimeList":[[1785288600000,1785297600000],[1785301200000,1785312000000]],"volumeRatio":1.610836,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02268","defaultTab":"news","newsList":[{"id":"1197790677","title":"异动解读｜药明合联盘中下跌3.04%，报52.7港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1197790677","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197790677?lang=zh_cn&edition=full","pubTime":"2026-07-28 11:12","pubTimestamp":1785208372,"startTime":"0","endTime":"0","summary":"7月28日，药明合联盘中下跌3.04%，报52.7港元/股，成交额6988.24万港元。药明合联所在的生命科学工具和服务行业中，板块整体承压，个股中，金斯瑞生物科技跌0.59%，药明康德跌0.32%，英矽智能跌7.79%，药明生物跌0.93%，晶泰控股跌4.18%。药明合联是一家主要从事抗体偶联药物（ADC）及其他生物偶联药物的全面合同研究、开发及制造组织（CRDMO）服务的投资控股公司，主要在国内市场、北美、欧洲和世界其他地区市场开展业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654458022","title":"【券商聚焦】交银国际：下半年医药板块有望迎来修复 但内部分化或持续加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2654458022","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654458022?lang=zh_cn&edition=full","pubTime":"2026-07-28 10:01","pubTimestamp":1785204072,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，近一个月恒生医疗保健指数涨17.4%，跑赢大市。其中，生物药、CXO及处方药板块表现较优于其他板块。机构持仓方面，2026年年中以来，内资持仓延续提升态势，而外资则略有降低。该机构指，中报季临近，7月以来多家公司业绩预告陆续发布，CXO板块表现亮眼，业绩和订单延续高增长态势。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986903","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276","06996","LU0856984785.SGD","06990","03329","09926","LU0572944931.SGD","02096","02269","01801","LU2476274308.USD","LU2399975544.HKD","LU1880383366.USD","01177","03692","09996","LU1813983027.USD","159938","01951","01548","LU2097828714.EUR","02162","09939","KCE","02273","HK0000320223.HKD","BK1219","LU2328871848.SGD","BK1587","LU0417516571.SGD","09966","01530","00013","06160","KURE","LU0634319403.HKD","LU2039709279.SGD","03759","01093","BK1521","LU0588546209.SGD","06078","HK0000165453.HKD","LU0196878994.USD","LU0348783233.USD","LU1720050803.USD","02268","02596","01952","06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149471454","title":"异动解读｜药明合联盘中下跌3.1%，报54.65港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1149471454","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149471454?lang=zh_cn&edition=full","pubTime":"2026-07-21 10:14","pubTimestamp":1784600057,"startTime":"0","endTime":"0","summary":"7月21日，药明合联盘中下跌3.1%，报54.65港元/股，成交额4708.23万港元。药明合联所在的生命科学工具和服务行业中，个股整体表现偏弱，其中英矽智能跌7.45%，晶泰控股跌4.58%，药明生物跌1.41%，药明康德跌1.34%，昭衍新药涨0.17%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162098983","title":"港股直击 | 生物医药股板块走强，荣昌生物、药明合联、康诺亚涨近8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1162098983","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162098983?lang=zh_cn&edition=full","pubTime":"2026-07-20 11:22","pubTimestamp":1784517729,"startTime":"0","endTime":"0","summary":"7月20日，生物医药股板块走强，荣昌生物、药明合联、康诺亚涨近8%，君实生物涨近7%，康方生物涨近6%，药明生物涨近5%。消息面上，创新药板块近期迎来多重催化。一方面，政策端持续释放支持信号，国务院发布《国民健康“十五五”规划》，提出加强创新药和医疗器械全链条支持，优化创新药及临床急需药品审评审批机制，进一步完善创新药发展环境。另一方面，国产创新药商业化和海外授权进展持续受到关注，工信部数据显示，今年上半年共有38款创新药获批上市，其中国产创新药占比超过80%。随着下半年全球医学会议密集召开，包括WCLC、ESMO、ASH等重要学术会议，部分创新药企业核心管线的临床数据将陆续披露，市场关注重点重新回到研发进展和商业化兑现能力。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269","09995","01877","02162","02268","02513","09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187532494","title":"异动解读｜药明合联盘中上涨6.94%，报57.0港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1187532494","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187532494?lang=zh_cn&edition=full","pubTime":"2026-07-20 11:03","pubTimestamp":1784516585,"startTime":"0","endTime":"0","summary":"7月20日，药明合联盘中上涨6.94%，报57.0港元/股，成交额1.82亿港元。药明合联所在的生命科学工具和服务行业中，个股整体表现偏强，其中英矽智能涨4.49%，药明生物涨4.27%，药明康德涨2.22%，晶泰控股涨1.95%，昭衍新药涨0.84%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652269822","title":"创新药板块活跃 荣昌生物(09995)涨7.28% 多支头部公募大举举牌港股创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2652269822","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652269822?lang=zh_cn&edition=full","pubTime":"2026-07-20 10:26","pubTimestamp":1784514372,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药板块活跃，荣昌生物 涨7.28%，歌礼制药-B涨6.81%，科伦博泰生物涨6.70%，康诺亚-B涨6.25%，康方生物涨5.83%，药明合联涨5.53%，石药集团涨4.94%，三生制药涨5.02%，信达生物涨4.55%，药明生物涨4.60%，恒瑞医药涨4.00%，百济神州涨3.88%。头部机构密集触及举牌线，凸显对创新药板块的看好。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986240","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268","LU1242518931.SGD","LU0043850808.USD","LU0708995583.HKD","09926","LU0979878070.USD","KCAI","06160","LU0348735423.USD","LU0417516738.SGD","LU1242518857.USD","LU0516422440.USD","BK1588","HK0000165453.HKD","01672","KURE","BK1576","IE00BZ08YT58.USD","LU0327786744.USD","BK0239","LU2097828474.EUR","02162","LU0516423174.USD","LU0052750758.USD","159992","IBBQ","BK1593","LU0359201612.USD","01276","01801","06990","LU1951186391.HKD","LU1226288170.HKD","LU2399975544.HKD","VXUS","MEDX","LU2328871848.SGD","01093","09995","02269","LU1064130708.USD","LU0348827113.USD","688331","01530","LU0516422366.SGD","BK4585","LU0196878994.USD","LU1720050803.USD","SG9999002463.SGD","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652735484","title":"药明合联因期权获行使而发行合计112.12万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652735484","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652735484?lang=zh_cn&edition=full","pubTime":"2026-07-17 08:24","pubTimestamp":1784247840,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　药明合联（02268）发布公告，于2026年7月16日，该公司根据公司于2023年3月22日采纳的2023年首次公开发售前购股权计划为行使期权而发行合计112.12万股普通股。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-07-17/doc-iniiahrk4202384.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["SG9999014674.SGD","LU2488822045.USD","BK1141","02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652478913","title":"药明合联(02268.HK)因期权获行使而发行合计112.12万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652478913","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652478913?lang=zh_cn&edition=full","pubTime":"2026-07-17 07:51","pubTimestamp":1784245906,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2488822045.USD","02268","BK1141","SG9999014674.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196282089","title":"药明合联：7月16日增发1,121,205股普通股，已发行股本相应变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1196282089","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196282089?lang=zh_cn&edition=full","pubTime":"2026-07-17 07:36","pubTimestamp":1784244962,"startTime":"0","endTime":"0","summary":"药明合联生物技术有限公司于2026年7月16日发布翌日披露报表，宣布公司已发行股本发生变动。根据公司于2023年3月22日采纳的2023年首次公开发售前购股权计划，当日因行使购股权先后增发1,000,000股及121,205股普通股，分别占前次已发行股份数目的约0.07904%及0.00958%，两次发行的每股价格均为每股港币4.8919元。本次发行前，公司于2026年7月15日的已发行股份为1,265,242,901股。完成上述增发后，截至2026年7月16日，公司已发行股份增至1,266,364,106股，库藏股份数为零。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药明合联：7月16日增发1,121,205股普通股，已发行股本相应变动","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651341039","title":"创新药连续大涨，这次真的不一样了吗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2651341039","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651341039?lang=zh_cn&edition=full","pubTime":"2026-07-16 17:05","pubTimestamp":1784192720,"startTime":"0","endTime":"0","summary":"政策上，医保初审通过率创新高，定价机制优化，并建立“医保+商保”双层支付体系；产业上，上半年BD交易总额达1100亿美元，国际竞争力显著提升；资金面上，内外资持续回流。行业正从“讲故事”转向盈利兑现，国金证券认为，2027年有望成为中国创新药海外商业化集中兑现的重要节点。","market":"hk","thumbnail":"https://static.tigerbbs.com/8daedf52c02cecfd417dcbd813afb3fa","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8daedf52c02cecfd417dcbd813afb3fa"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3777107","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622","159992","MEDX","09688","02268","03759","BK1161","09606","02137","03347","09966","02269","06978","BK1574","IBBQ","01672","00241","06606","09995","06996","02359","06618","01801"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1117216926","title":"药明合联：合计增发1,133,511股，已发行股本升至约12.65亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=1117216926","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117216926?lang=zh_cn&edition=full","pubTime":"2026-07-15 21:01","pubTimestamp":1784120497,"startTime":"0","endTime":"0","summary":"根据药明合联于2026年7月15日发布的公告，公司于同日因行使购股权合计增发1,133,511股新股，占此前已发行股本约0.09%。增发价格区间介乎每股1.80港元至7.50港元。本次变动后，公司已发行股本从约12.64亿股增至约12.65亿股，且暂无库藏股。\n公告显示，本次股本变动主要缘于公司根据2021年11月23日采纳的2021年首次公开发售前购股权计划及2023年3月22日采纳的2023年首次公开发售前购股权计划，为相关参与人及公司董事行使期权而新发行普通股。公司确认已遵守香港联合交易所有限公司证券上市规则及相关法律法规的所有适用规定。\n本公告由执行董事兼首席财务官席晓捷签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药明合联：合计增发1,133,511股，已发行股本升至约12.65亿股","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651656254","title":"药明合联(02268)根据股份计划发行合计113.35万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651656254","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651656254?lang=zh_cn&edition=full","pubTime":"2026-07-15 20:58","pubTimestamp":1784120319,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药明合联(02268)发布公告，于2026年7月15日根据股份计划发行合计113.35万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468106.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999014674.SGD","BK1141","02268","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651810439","title":"港股早盘高开高走 恒指半日涨1.46% 创新药、猪肉概念强势","url":"https://stock-news.laohu8.com/highlight/detail?id=2651810439","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651810439?lang=zh_cn&edition=full","pubTime":"2026-07-15 12:11","pubTimestamp":1784088667,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股早盘高开高走，三大股指均升逾1%。截至午间收盘，恒生指数上涨1.46%；国企指数涨1.16%；恒生科技指数涨1.39%。猪价底部大概率已现，预计周期临近上行。预计2026年半年度归属于上市公司股东的扣除非经常性损益的净利润约为人民币20.00亿元到人民币26.00亿元，与上年同期相比，将增加人民币18.62亿元到人民币24.62亿元，同比增长1349%到1784%。MiniMax盘中反复拉升，午间收涨14.96%。港股将受益于中国内地强劲而有韧性的经济表现，建议超配H股。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/YWY0NWM4YTUxZGFlZmZjNmE5MDYxNjI4NjU1Mjc3NzM1Mzg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YWY0NWM4YTUxZGFlZmZjNmE5MDYxNjI4NjU1Mjc3NzM1Mzg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985921","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0708995583.HKD","LU0307460666.USD","LU0048597586.USD","LU1634259557.SGD","02269","601869","LU0441854154.USD","IE00BWDBJ730.SGD","LU2097828474.EUR","LU0072913022.USD","LU2476274720.SGD","BK1237","BK1226","IE00BPRC5H50.USD","LU0348766576.USD","LU0819121731.USD","LU1720050803.USD","IE00BZ08YR35.GBP","07300","LU0516422440.USD","LU0651946864.USD","LU0651947912.USD","LU3063872942.SGD","SG9999003461.SGD","LU0315178854.USD","00100","BK1506","LU1303224171.USD","02628","BK1583","83115","LU1808992512.USD","LU0516422366.SGD","01610","01477","BK1117","LU0228367735.SGD","LU2328871848.SGD","LU0287142896.SGD","LU1046422090.SGD","07500","LU1719994722.HKD","LU0359201885.HKD","LU0821914370.USD","LU0516423091.SGD","LU2257852520.SGD","LU1226288253.USD","01928","SGXZ62798434.SGD","600028","LU0051755006.USD","BK1610","LU0463099449.HKD","BK1550","LU1008478684.HKD","IE00B031HY20.USD","LU0196878994.USD","LU1152091168.USD","BK1614","BK1184","LU1051768304.USD","LU0405327494.USD","SG9999002562.SGD","BK1163","LU0327786744.USD","LU1969619763.USD","LU1497733557.USD","IE00B0JY6N72.USD","LU2045819591.USD","LU0828237940.HKD","SG9999004220.SGD","SG9999012710.SGD","LU0348784397.USD","02833","SG9999001226.SGD","LU0164865239.USD","LU1880383366.USD","00981","LU0890818403.SGD","LU0516422952.EUR","LU0675040207.SGD","BK1521","HK0000286598.CNH","SG9999001093.SGD","BK1161","LU0405327148.USD","SG9999002463.SGD","IE00B19Z5X02.USD","LU1522347837.USD","LU0211977185.USD","IE00B5MMRT66.SGD","LU0501845795.SGD","LU0862451753.SGD","603259","02268","IE00B543WZ88.USD","SCHYY","BK1528","03037","LU0348827113.USD","LU0072462343.USD","LU0320764599.SGD","LU1048596156.SGD","01177","SG9999014674.SGD","LU0293314216.USD","HSI","LU0348805143.USD","02800","03115","IE00BQJZWZ67.USD","02359","LU0588545904.SGD","LU1675838814.USD","SBHMY","LU0348783662.USD","MCHmain","BK1562","IE0008368742.USD","WXXWY","HHImain","LU1961090484.USD","601857","LU1023057109.AUD","BK1584","LU2097828714.EUR","BK1589","LU1497734951.SGD","LU0572944931.SGD","LU2242644610.SGD","06869","LU1807302812.USD","LU2039709279.SGD","LU1226287792.SGD","SG9999012736.USD","IE00BZ08YT58.USD","02714","LU0359201612.USD","BK1149","LU0169518387.USD","LU0516423174.USD","LU0326950275.SGD","09926","LU1251922891.USD","BK1523","LU1242518931.SGD","LU0634319403.HKD","LU0880133367.SGD","LU0315179316.USD","LU0348735423.USD","LU0417516738.SGD","BK1526","LU0862451837.USD","LU1328277881.USD","LU1813983027.USD","LU0163747925.USD","LU0979878070.USD","LU1242518857.USD","LU0588546209.SGD","03419","BK1576","LU2097828557.USD","601628","LU0502904849.HKD","BK1607","LU1211504680.USD","00386","BK1141","BK1191","HK0000165453.HKD","LU2488822045.USD","LU2125910500.SGD","LU1048588211.SGD","LU2097828631.EUR","LU0052750758.USD","07200","LU0417516571.SGD","002714","LU0640798160.USD","LU0823426480.USD","LU2399975544.HKD","LU0456846285.SGD","SG9999012744.USD","LU0823426308.USD","LU1226287529.USD","BK1172","LU1515016050.SGD","LU0181495838.USD","SG9999006597.SGD","IE0008369823.USD","LU1794554557.SGD","LU1226288170.HKD","BK1549","LU1770034418.SGD","LU2097828805.USD","IE00BZ08YS42.EUR","LU0173614495.USD","LU1188198961.HKD","01093","LU0456827905.SGD","LU1282651048.USD","LU2778985437.USD","00857","BK1515","BK1603","LU0140636845.USD","LU0469268626.HKD","LU0588545730.USD","LU1960683339.HKD","BK1574","LU0348767384.USD","LU0588545490.SGD","LU0540923850.HKD","KURE","SG9999012728.SGD","LU0067412154.USD","SGXZ86797644.SGD","LU1634259391.SGD","IE0032431581.USD","LU2476274308.USD","LU1226287875.USD","LU0865486749.SGD","09115","LU0359202008.SGD","01801","LU0348783233.USD","LU0871576103.HKD","LU1224444064.USD","LU1282651121.HKD","LU1688375341.USD","LU1051769294.HKD","LU0314109678.HKD","LU2293587155.HKD","LU0531971595.HKD","LU0348825331.USD","LU0561508036.HKD","LU1831875114.USD","513600","LU1115378108.SGD","LU0611395673.USD","LU0039217434.USD","02419","06990","LU0856984785.SGD","LU1785774172.SGD","LU1497733631.SGD","LU1993786604.SGD","LU1951186391.HKD","LU1152091754.HKD","LU0043850808.USD","LU0251144936.SGD","HSTECH","LU0972618739.USD","688981","82800","LU0417516902.SGD","LU0455707207.USD","LU0244354667.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651291435","title":"创新药概念全线扬升 科伦博泰生物(06990)涨逾11% 机构指创新药企迎业绩兑现窗口","url":"https://stock-news.laohu8.com/highlight/detail?id=2651291435","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651291435?lang=zh_cn&edition=full","pubTime":"2026-07-15 11:07","pubTimestamp":1784084836,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股创新药概念盘中全线扬升，截至发稿，欧康维视生物-B 涨13.35%，科伦博泰生物涨11.20%，康方生物涨8.82%，信达生物涨8.72%，三生制药涨8.11%，康诺亚-B涨7.62%，药明合联涨7.52%，荣昌生物涨7.09%，乐普生物涨6.87%，亚盛医药涨6.26%。该机构持续看好国内创新药出海β向上可持续性，提示投资者关注2027年起众多前期已达成BD的分子将在海外开启商业化新周期所带来的投资机会。","market":"fut","thumbnail":"https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985914","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720050803.USD","LU2097828714.EUR","06855","01477","09926","IE00BPRC5H50.USD","02157","LU2488822045.USD","02162","BK1589","159992","LU2097828805.USD","MEDX","BK1141","LU0417516571.SGD","SG9999014674.SGD","IE00B543WZ88.USD","BK1593","LU0348825331.USD","LU0561508036.HKD","LU0540923850.HKD","KURE","LU0348784397.USD","06990","LU0348827113.USD","LU0502904849.HKD","LU1961090484.USD","LU0634319403.HKD","BK1574","LU2399975544.HKD","LU2778985437.USD","BK1587","LU2097828474.EUR","BK1191","06978","01530","LU2476274308.USD","BK1161","LU0417516902.SGD","09995","LU0348767384.USD","LU2328871848.SGD","01801","LU0417516738.SGD","LU2097828631.EUR","LU2097828557.USD","BK1583","IBBQ","02268","LU0455707207.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153301018","title":"异动解读｜药明合联盘中上涨3.5%，CXO板块集体走强延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1153301018","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153301018?lang=zh_cn&edition=full","pubTime":"2026-07-15 09:42","pubTimestamp":1784079734,"startTime":"0","endTime":"0","summary":"7月15日，药明合联盘中上涨3.5%，报60.7港元，成交额3126.26万港元。消息面上，CXO板块延续强势，同行业个股中康龙化成涨6.61%、药明康德涨3.42%、药明生物涨3.25%、昭衍新药涨12.61%，板块共振效应显著。近期多家国际投行集中发布正面研报，交银国际最新给予\"增持\"评级，目标价80港元；此前里昂上调目标价至82.6港元维持\"跑赢大市\"评级，大和首予\"买入\"评级并列为中国CXO行业首选股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139376685","title":"药明合联：发行逾200万股新股，总股本增至12.64亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=1139376685","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139376685?lang=zh_cn&edition=full","pubTime":"2026-07-14 22:01","pubTimestamp":1784037705,"startTime":"0","endTime":"0","summary":"药明合联(02268)于2026年7月14日公告，于2026年7月6日至2026年7月14日期间，分别根据该公司于2021年11月23日及2023年3月22日采纳的首次公开发售前购股权计划，合计发行2,004,133股普通股，约占该公司原已发行股本的0.16%。新股发行价格介乎每股1.8024港元至7.501港元。\n上述股份变动后，公司已发行股本由1,262,105,257股增至1,264,109,390股，库藏股份数量维持为零。公司在公告中确认已获得董事会正式授权，并遵守香港联合交易所有限公司证券上市规则及相关法律规定。\n公告由执行董事兼首席财务官席晓捷先生签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药明合联：发行逾200万股新股，总股本增至12.64亿股","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651101606","title":"药明合联(02268.HK)根据股份计划发行合计200.4万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651101606","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651101606?lang=zh_cn&edition=full","pubTime":"2026-07-14 21:58","pubTimestamp":1784037531,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2488822045.USD","BK1141","SG9999014674.SGD","02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194479249","title":"异动解读｜药明合联盘中上涨3.05%，CXO板块集体走强带动","url":"https://stock-news.laohu8.com/highlight/detail?id=1194479249","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194479249?lang=zh_cn&edition=full","pubTime":"2026-07-14 14:39","pubTimestamp":1784011196,"startTime":"0","endTime":"0","summary":"7月14日，药明合联盘中上涨3.05%，报59.2港元，成交额2.49亿港元。消息面上，近期多家国际投行集中发布正面研报，里昂将目标价上调至82.6港元并维持\"跑赢大市\"评级，大和首予\"买入\"评级并列为中国CXO行业首选股，目标价78港元。同日生命科学工具和服务板块整体走强，康龙化成涨6.58%、药明康德涨5.61%、药明生物涨3.22%，板块共振效应延续。基本面方面，公司未完成订单约14.89亿美元，同比增长50.3%，全球ADC外包市场份额持续提升，盈利可见性增强。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651167818","title":"【特约大V】邓声兴：美伊烽火再起，恒指本周料承压整固","url":"https://stock-news.laohu8.com/highlight/detail?id=2651167818","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651167818?lang=zh_cn&edition=full","pubTime":"2026-07-13 10:23","pubTimestamp":1783909405,"startTime":"0","endTime":"0","summary":"金吾财讯 | 恒指周五 收市报24175点，升144点或0.6%。美伊烽火再起，恒指本周料承压整固。华虹作为全球产能排名第一的功率器件代工企业及国内最大MCU制造代工企业，正处于内部资产整合与外部行业景气双重驱动的盈利拐点，量价共振下估值具备重估空间，投资者宜密切跟进并购完成进度及毛利率修复趋势。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/MTBhNmJhMjNhYmJjNDg2MTczNjQ3NDEwNzUzMg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MTBhNmJhMjNhYmJjNDg2MTczNjQ3NDEwNzUzMg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985671","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07500","BK1607","03419","LU1046422090.SGD","SG9999014674.SGD","06745","09115","BK1576","07300","TCHI","LU2045819591.USD","LU2242644610.SGD","HSImain","LU2488822045.USD","SG9999006597.SGD","HSI","LU0708995583.HKD","HHImain","02268","LU0348766576.USD","LU0320764599.SGD","BK1614","MCHmain","82800","LU2125910500.SGD","03115","BK1589","LU0052750758.USD","LU0348767384.USD","BK1110","07200","513600","MHImain","02249","BK1583","02833","BK1163","IE0034224299.USD","BK1141","03037","02800","02359","01347","83115"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164627014","title":"药明合联（02268）拟于8月24日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1164627014","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164627014?lang=zh_cn&edition=full","pubTime":"2026-07-10 17:06","pubTimestamp":1783674366,"startTime":"0","endTime":"0","summary":"药明合联（02268）7月10日公告称，公司董事会将于2026年8月24日（星期一）召开会议，届时将审议并批准集团截至2026年6月30日止六个月的中期业绩及其发布事宜。董事会名单包括执行董事李锦才博士、张靖伟先生、席晓捷先生；非执行董事陈智胜博士、顾继杰博士、施明女士；以及独立非执行董事Ulf Grawunder博士、Kenneth Walton Hitchner III先生与Hao Zhou先生。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://wuxixdc.com","stockEarnings":[{"period":"1week","weight":-0.0349},{"period":"1month","weight":-0.02},{"period":"3month","weight":-0.0794},{"period":"6month","weight":-0.1637},{"period":"1year","weight":-0.0849},{"period":"ytd","weight":-0.1128}],"compareEarnings":[{"period":"1week","weight":0.0071},{"period":"1month","weight":0.1164},{"period":"3month","weight":-0.0307},{"period":"6month","weight":-0.095},{"period":"1year","weight":-0.0098},{"period":"ytd","weight":-0.0125}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药明合联生物技术有限公司是一家主要从事提供提供抗体偶联药物（ADC）及其他生物偶联药物的全面合同研究、开发及制造组织（CRDMO）服务的投资控股公司。该公司的服务包括生物偶联药物、单克隆抗体中间体及生物偶联药物相关连接子及有效载荷的发现、工艺开发及优良生产质量管理规范（GMP）生产。该公司透过按有偿服务（FFS）基准的合约和按全时当量（FTE）基准的合约向客户提供CRDMO服务。该公司主要在国内市场、北美、欧洲和世界其他地区市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.222222,"avgChangeRate":0.010265},{"month":2,"riseRate":0.666667,"avgChangeRate":0.058284},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.010372},{"month":4,"riseRate":0.555556,"avgChangeRate":0.03555},{"month":5,"riseRate":0.333333,"avgChangeRate":0.006014},{"month":6,"riseRate":0.4,"avgChangeRate":-0.032735},{"month":7,"riseRate":0.4,"avgChangeRate":0.011785},{"month":8,"riseRate":0.4,"avgChangeRate":-0.114063},{"month":9,"riseRate":0.333333,"avgChangeRate":0.019767},{"month":10,"riseRate":0.777778,"avgChangeRate":0.151657},{"month":11,"riseRate":0.333333,"avgChangeRate":0.008796},{"month":12,"riseRate":0.111111,"avgChangeRate":-0.068876}],"exchange":"SEHK","name":"药明合联","nameEN":"WUXI XDC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明合联,02268,药明合联股票,药明合联股票老虎,药明合联股票老虎国际,药明合联行情,药明合联股票行情,药明合联股价,药明合联股市,药明合联股票价格,药明合联股票交易,药明合联股票购买,药明合联股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}